Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials

Associations between body mass index (BMI) and the cardiovascular (CV) and kidney efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) in patients with type 2 diabetes (T2D) are uncertain; therefore, data analysed separately from the Liraglutide Effect and Action in Diabetes: Evaluation...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Subodh, McGuire, Darren K., Bain, Stephen C., Bhatt, Deepak L., Leiter, Lawrence A., Mazer, C. David, Monk Fries, Tea, Pratley, Richard E., Rasmussen, Søren, Vrazic, Hrvoje, Zinman, Bernard, Buse, John B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754406/
https://www.ncbi.nlm.nih.gov/pubmed/32744418
http://dx.doi.org/10.1111/dom.14160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754406/
https://www.ncbi.nlm.nih.gov/pubmed/32744418
http://dx.doi.org/10.1111/dom.14160

Ejemplares similares